NAFLD leads to liver cancer: Do we have sufficient evidence?

Cancer Letters

Volumn 345, Issue 2, 2014, Pages 230-234

  Duan, Xiao Yan ^a   Zhang, Lei ^b   Fan, Jian Gao ^a   Qiao, Liang ^c  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b LANZHOU UNIVERSITY   (China)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Fatty liver; Hepatocellular carcinoma; Liver cancer; Nonalcoholic steatohepatitis

Indexed keywords

CANCER RISK; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; HEPATITIS B; HEPATITIS C; HUMAN; INSULIN RESISTANCE; IRON OVERLOAD; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CIRRHOSIS; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; RISK FACTOR; SHORT SURVEY;

HEPATITIS B VIRUS; HEPATITIS C VIRUS;

FATTY LIVER; HEPATOCELLULAR CARCINOMA; LIVER CANCER; NONALCOHOLIC STEATOHEPATITIS;

CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; FATTY LIVER; HUMANS; INFLAMMATION MEDIATORS; LIVER NEOPLASMS; PROGNOSIS; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84896723435     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.07.033     Document Type: Review

References (86)

1. Powell E.E., Cooksley W.G., Hanson R., Searle J., Halliday J.W., Powell L.W. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21years. Hepatology 1990, 11:74-80.
2. Bugianesi E. Non-alcoholic steatohepatitis and cancer. Clin. Liver Dis. 2007, 11:191-207. x-xi.
3. Page J.M., Harrison S.A. NASH and HCC. Clin. Liver Dis. 2009, 13:631-647.
4. Starley B.Q., Calcagno C.J., Harrison S.A. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010, 51:1820-1832.
5. Baffy G., Brunt E.M., Caldwell S.H. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J. Hepatol. 2012, 56:1384-1391.
6. Rosmorduc O., Fartoux L. HCC and NASH: how strong is the clinical demonstration?. Clin. Res. Hepatol. Gastroenterol. 2012, 36:202-208.
7. White D.L., Kanwal F., El-Serag H.B. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin. Gastroenterol. Hepatol. 2012, 10:1342-1359.
8. S. De Minicis, C. Day, G. Svegliati-Baroni, From NAFLD to NASH and HCC: pathogenetic mechanisms and therapeutic insights, Curr. Pharm. Des. (2013) (Epub ahead of print).
9. Cotrim H.P., Paraná R., Braga E., Lyra L. Nonalcoholic steatohepatitis and hepatocellular carcinoma: natural history?. Am. J. Gastroenterol. 2000, 95:3018-3019.
10. Zen Y., Katayanagi K., Tsuneyama K., Harada K., Araki I., Nakanuma Y. Hepatocellular carcinoma arising in non-alcoholic steatohepatitis. Pathol. Int. 2001, 51:127-131.
11. Orikasa H., Ohyama R., Tsuka N., Eyden B.P., Yamazaki K. Lipid-rich clear-cell hepatocellular carcinoma arising in non-alcoholic steatohepatitis in a patient with diabetes mellitus. J. Submicrosc. Cytol. Pathol. 2001, 33:195-200.
12. Shimada M., Hashimoto E., Taniai M., Hasegawa K., Okuda H., Hayashi N., Takasaki K., Ludwig J. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J. Hepatol. 2002, 37:154-160.
13. Yoshioka Y., Hashimoto E., Yatsuji S., Kaneda H., Taniai M., Tokushige K., Shiratori K. Nonalcoholic steatohepatitis: cirrhosis, hepatocellular carcinoma, and burnt-out NASH. J. Gastroenterol. 2004, 39:1215-1218.
14. Bencheqroun R., Duvoux C., Luciani A., Zafrani E.S., Dhumeaux D. Hepatocellular carcinoma without cirrhosis in a patient with nonalcoholic steatohepatitis. Gastroenterol. Clin. Biol. 2004, 28:497-499.
15. Mori S., Yamasaki T., Sakaida I., Takami T., Sakaguchi E., Kimura T., Kurokawa F., Maeyama S., Okita K. Hepatocellular carcinoma with nonalcoholic steatohepatitis. J. Gastroenterol. 2004, 39:391-396.
16. Bullock R.E., Zaitoun A.M., Aithal G.P., Ryder S.D., Beckingham I.J., Lobo D.N. Association of non-alcoholic steatohepatitis without significant fibrosis with hepatocellular carcinoma. J. Hepatol. 2004, 41:685-690.
17. Cuadrado A., Orive A., García-Suárez C., Domínguez A., Fernández-Escalante J.C., Crespo J., Pons-Romero F. Non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma. Obes. Surg. 2005, 15:426-442.
18. Sato K., Ueda Y., Ueno K., Okamoto K., Iizuka H., Katsuda S. Hepatocellular carcinoma and nonalcoholic steatohepatitis developing during long-term administration of valproic acid. Virchows Arch. 2005, 447:996-999.
19. Ikeda H., Suzuki M., Takahashi H., Kobayashi M., Okuse N., Moriya H., Koike J., Maeyama S., Yotsuyanagi H., Itoh F. Hepatocellular carcinoma with silent and cirrhotic non-alcoholic steatohepatitis, accompanying ectopic liver tissue attached to gallbladder. Pathol. Int. 2006, 56:40-45.
20. Hai S., Kubo S., Shuto T., Tanaka H., Takemura S., Yamamoto T., Kanazawa A., Ogawa M., Hirohashi K., Wakasa K. Hepatocellular carcinoma arising from nonalcoholic steatohepatitis: report of two cases. Surg. Today 2006, 36:390-394.
21. Ichikawa T., Yanagi K., Motoyoshi Y., Hamasaki K., Nakao K., Toriyama K., Eguchi K. Two cases of non-alcoholic steatohepatitis with development of hepatocellular carcinoma without cirrhosis. J. Gastroenterol. Hepatol. 2006, 21:1865-1866.
22. Tsutsumi K., Nakayama H., Sakai Y., Kojima Y., Dairaku N., Ojima T., Kusano M., Ikeya S., Sugai Y., Hiwatashi N. Two cases of patients with hepatocellular carcinoma (HCC) that developed in cryptogenic cirrhosis suggestive of nonalcoholic steatohepatitis (NASH) as background liver disease after clinical courses of 26years. Nippon Shokakibyo Gakkai Zasshi 2007, 104:690-697.
23. Hashizume H., Sato K., Takagi H., Hirokawa T., Kojima A., Sohara N., Kakizaki S., Mochida Y., Shimura T., Sunose Y., Ohwada S., Mori M. Primary liver cancers with nonalcoholic steatohepatitis. Eur. J. Gastroenterol. Hepatol. 2007, 19:827-834.
24. Iannaccone R., Piacentini F., Murakami T., Paradis V., Belghiti J., Hori M., Kim T., Durand F., Wakasa K., Monden M., Nakamura H., Passariello R., Vilgrain V. Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: helical CT and MR imaging findings with clinical-pathologic comparison. Radiology 2007, 243:422-430.
25. Maeda T., Hashimoto K., Kihara Y., Ikegami T., Ishida T., Aimitsu S., Fujiwara M. Surgically resected hepatocellular carcinomas in patients with non-alcoholic steatohepatitis. Hepatogastroenterology 2008, 55:1404-1406.
26. Hashimoto E., Yatsuji S., Tobari M., Taniai M., Torii N., Tokushige K., Shiratori K. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J. Gastroenterol. 2009, 44:89-95.
27. Kawada N., Imanaka K., Kawaguchi T., Tamai C., Ishihara R., Matsunaga T., Gotoh K., Yamada T., Tomita Y. Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis. J. Gastroenterol. 2009, 44:1190-1194.
28. Malik S.M., Gupte P.A., de Vera M.E., Ahmad J. Liver transplantation in patients with nonalcoholic steatohepatitis related hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 2009, 7:800-806.
29. Chagas A.L., Kikuchi L.O., Oliveira C.P., Vezozzo D.C., Mello E.S., Oliveira A.C., Cella L.C., Herman P., Bachella T., Caldwell S.H., Alves V.A., Carrilho F.J. Does hepatocellular carcinoma in non-alcoholic steatohepatitis exist in cirrhotic and noncirrhotic patients?. Braz. J. Med. Biol. Res. 2009, 42:958-962.
30. Takuma Y., Nouso K. Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: our case series and literature review. World J. Gastroenterol. 2010, 16:1436-1441.
31. Ertle J., Dechêne A., Sowa J.P., Penndorf V., Herzer K., Kaiser G., Schlaak J.F., Gerken G., Syn W.K., Canbay A. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int. J. Cancer 2011, 128:2436-2443.
32. Bugianesi E., Leone N., Vanni E., Marchesini G., Brunello F., Carucci P., Musso A., De Paolis P., Capussotti L., Salizzoni M., Rizzetto M. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002, 123:134-140.
33. Sanyal A., Poklepovic A., Moyneur E., Barghout V. Population-based risk factors and resource utilization for HCC: US perspective. Curr. Med. Res. Opin. 2010, 26:2183-2191.
34. Yang J.D., Harmsen W.S., Slettedahl S.W., Chaiteerakij R., Enders F.T., Therneau T.M., Orsini L., Kim W.R., Roberts L.R. Factors that affect risk for hepatocellular carcinoma and effects of surveillance. Clin. Gastroenterol. Hepatol. 2011, 9(7):617-623.
35. Tokushige K., Hashimoto E., Yatsuji S., Tobari M., Taniai M., Torii N., Shiratori K. Prospective study of hepatocellular carcinoma in nonalcoholic steatohepatitis in comparison with hepatocellular carcinoma caused by chronic hepatitis C. J. Gastroenterol. 2010, 45:960-967.
36. Adams L.A., Lymp J.F., St Sauver J., Sanderson S.O., Lindor K.D., Feldstein A., Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005, 129:113-121.
37. Matteoni C.A., Younossi Z.M., Gramlich T., Boparai N., Liu Y.C., McCullough A.J. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116:1413-1419.
38. Ekstedt M., Franzén L.E., Mathiesen U.L., Thorelius L., Holmqvist M., Bodemar G., Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44:865-873.
39. Nakanishi Y., Tsuneyama K., Nomoto K., Fujimoto M., Salunga T.L., Nakajima T., Miwa S., Murai Y., Hayashi S., Kato I., Hiraga K., Hsu D.K., Liu F.T., Takano Y. Nonalcoholic steatohepatitis and hepatocellular carcinoma in galectin-3 knockout mice. Hepatol. Res. 2008, 38:1241-1251.
40. Shiota G. Role of retinoic acid receptor in steatohepatitis-related tumor formation. J. Gastroenterol. Hepatol. 2007, 22(Suppl. 1):S101-S107.
41. Seki E., Brenner D.A. The role of NF-kappaB in hepatocarcinogenesis: promoter or suppressor?. J. Hepatol. 2007, 47:307-309.
42. Luedde T., Beraza N., Kotsikoris V., van Loo G., Nenci A., De Vos R., Roskams T., Trautwein C., Pasparakis M. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 2007, 11:119-132.
43. Watanabe S., Horie Y., Kataoka E., Sato W., Dohmen T., Ohshima S., Goto T., Suzuki A. Non-alcoholic steatohepatitis and hepatocellular carcinoma: lessons from hepatocyte-specific phosphatase and tensin homolog (PTEN)-deficient mice. J. Gastroenterol. Hepatol. 2007, 22(Suppl. 1):S96-S100.
44. Stiles B., Wang Y., Stahl A., Bassilian S., Lee W.P., Kim Y.J., Bassilian S., Lee W.P., Kim Y.J., Sherwin R., Devaskar S., Lesche R., Magnuson M.A., Wu H. Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity. Proc. Natl. Acad. Sci. USA 2004, 101:2082-2087.
45. Martínez-Chantar M.L., Vázquez-Chantada M., Ariz U., Martínez N., Varela M., Luka Z., Capdevila A., Rodríguez J., Aransay A.M., Matthiesen R., Yang H., Calvisi D.F., Esteller M., Fraga M., Lu S.C., Wagner C., Mato J.M. Loss of the glycine N-methyltransferase gene leads to steatosis and hepatocellular carcinoma in mice. Hepatology 2008, 47:1191-1199.
46. Nishida T., Tsuneyama K., Fujimoto M., Nomoto K., Hayashi S., Miwa S., Nakajima T., Nakanishi Y., Sasaki Y., Suzuki W., Iizuka S., Nagata M., Shimada T., Aburada M., Shimada Y., Imura J. Spontaneous onset of nonalcoholic steatohepatitis and hepatocellular carcinoma in a mouse model of metabolic syndrome. Lab. Invest. 2013, 93:230-241.
47. N. Bhala, R.I. Jouness, E. Bugianesi, Epidemiology and natural history of patients with NAFLD, Curr. Pharm. Des. 4 (2013) (Epub ahead of print).
48. Harrison S.A., Torgerson S., Hayashi P.H. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am. J. Gastroenterol. 2003, 98:2042-2047.
49. Adams L.A., Sanderson S., Lindor K.D., Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J. Hepatol. 2005, 42:132-138.
50. Fassio E., Alvarez E., Dominguez N., Landeira G., Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 2004, 40:820-826.
51. Lindor K.D., Kowdley K.V., Heathcote E.J., Harrison M.E., Jorgensen R., Angulo P., Lymp J.F., Burgart L., Colin P. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004, 39:770-778.
52. Yasui K., Hashimoto E., Komorizono Y., Koike K., Arii S., Imai Y., Shima T., Kanbara Y., Saibara T., Mori T., Kawata S., Uto H., Takami S., Sumida Y., Takamura T., Kawanaka M., Okanoue T. Japan NASH Study Group, Ministry of Health, Labour, and Welfare of Japan, characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 2011, 9:428-433.
53. Duan X.Y., Qiao L., Fan J.G. Clinical features of nonalcoholic fatty liver disease-associated hepatocellular carcinoma. Hepatobiliary Pancreat. Dis. Int. 2012, 11:18-27.
54. Ratziu V., Bonyhay L., Di Martino V., Charlotte F., Cavallaro L., Sayegh-Tainturier M.H., Giral P., Grimaldi A., Opolon P., Poynard T. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002, 35:1485-1493.
55. Alexander J., Torbenson M., Wu T.T., Yeh M.M. Non-alcoholic fatty liver disease contributes to hepatocarcinogenesis in non-cirrhotic liver: a clinical and pathological study. J. Gastroenterol. Hepatol. 2013, 28:848-854.
56. Rahman R. Nonalcoholic fatty liver disease without cirrhosis is anemergent and independent risk factor of hepatocellular carcinoma: a population based study. Hepatology 2012, 56:191A-1144A.
57. Rafiq N., Bai C., Fang Y., Srishord M., McCullough A., Gramlich T. Long-term follow-up of patients with nonalcoholic fatty liver. Clin. Gastroenterol. Hepatol. 2009, 7:234-238.
58. Fan J.G., Farrell G.C. Asia-Pacific working party for prevention of hepatocellular carcinoma, prevention of hepatocellular carcinoma in nonviral-related liver diseases. J. Gastroenterol. Hepatol. 2009, 24:712-719.
59. Bugianesi E. Review article: steatosis, the metabolic syndrome and cancer. Aliment Pharmacol. Ther. 2005, 22(Suppl. 2):40-43.
60. Lim Y.S., Kim W.R. The global impact of hepatic fibrosis and end-stage liver disease. Clin. Liver Dis. 2008, 12:733-746. vii.
61. Yatsuji S., Hashimoto E., Tobari M., Taniai M., Tokushige K., Shiratori K. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J. Gastroenterol. Hepatol. 2009, 24:248-254.
62. Ascha M.S., Hanouneh I.A., Lopez R., Tamimi T.A., Feldstein A.F., Zein N.N. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010, 51:1972-1978.
63. Blonski W., Kotlyar D.S., Forde K.A. Non-viral causes of hepatocellular carcinoma. World J. Gastroenterol. 2010, 16:3603-3615.
64. Polesel J., Zucchetto A., Montella M., Dal Maso L., Crispo A., La Vecchia C., Serraino D., Franceschi S., Talamini R. The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. Ann. Oncol. 2009, 20:353-357.
65. El-Serag H.B., Tran T., Everhart J.E. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004, 126:460-468.
66. Kawamura Y., Ikeda K., Arase Y., Yatsuji H., Sezaki H., Hosaka T., Akuta N., Kobayashi M., Saitoh S., Suzuki F., Suzuki Y., Kumada H. Diabetes mellitus worsens the recurrence rate after potentially curative therapy in patients with hepatocellular carcinoma associated with nonviral hepatitis. J. Gastroenterol. Hepatol. 2008, 23:1739-1746.
67. Komura T., Mizukoshi E., Kita Y., Sakurai M., Takata Y., Arai K., Yamashita T., Ohta T., Shimizu K., Nakamoto Y., Honda M., Takamura T., Kaneko S. Impact of diabetes on recurrence of hepatocellular carcinoma after surgical treatment in patients with viral hepatitis. Am. J. Gastroenterol. 2007, 102:1939-1946.
68. Tung H.D., Wang J.H., Tseng P.L., Hung C.H., Kee K.M., Chen C.H., Chang K.C., Lee C.M., Changchien C.S., Chen Y.D., Lu S.N. Neither diabetes mellitus nor overweight is a risk factor for hepatocellular carcinoma in a dual HBV and HCV endemic area: community cross-sectional and case-control studies. Am. J. Gastroenterol. 2010, 105:624-631.
69. El-Serag H.B. Epidemiology of hepatocellular carcinoma. Clin. Liver Dis. 2001, 5:87-107.
70. Davila J.A. Diabetes and hepatocellular carcinoma: what role does diabetes have in the presence of other known risk factors?. Am. J. Gastroenterol. 2010, 105:632-634.
71. Qian Y., Fan J.G. Obesity, fatty liver and liver cancer. Hepatobiliary Pancreat. Dis. Int. 2005, 4:173-177.
72. Gurevich-Panigrahi T., Panigrahi S., Wiechec E., Los M. Obesity: pathophysiology and clinical management. Curr. Med. Chem. 2009, 16:506-521.
73. Shetty P., Schmidhuber J. Introductory lecture the epidemiology and determinants of obesity in developed and developing countries. Int. J. Vitam. Nutr. Res. 2006, 76:157-162.
74. Larsson S.C., Wolk A. Overweight obesity and risk of liver cancer: a meta-analysis of cohort studies. Br. J. Cancer 2007, 97:1005-1008.
75. Ohishi W., Fujiwara S., Cologne J.B., Suzuki G., Akahoshi M., Nishi N., Takahashi I., Chayama K. Risk factors for hepatocellular carcinoma in a Japanese population: a nested case-control study. Cancer Epidemiol. Biomarkers Prev. 2008, 17:846-854.
76. Shen C., Zhao C.Y., Zhang R., Qiao L. Obesity-related hepatocellular carcinoma: roles of risk factors altered in obesity. Front Biosci. 2012, 17:2356-2370.
77. Chen C.L., Yang H.I., Yang W.S., Liu C.J., Chen P.J., You S.L., Wang L.Y., Sun C.A., Lu S.N., Chen D.S., Chen C.J. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008, 135:111-121.
78. Vongsuvanh R., George J., Qiao L., van der Poorten D. Visceral adiposity in gastrointestinal and hepatic carcinogenesis. Cancer Lett. 2013, 330:1-10.
79. Petta S., Craxì A. Hepatocellular carcinoma and non-alcoholic fatty liver disease: from a clinical to a molecular association. Curr. Pharm. Des. 2010, 16:741-752.
80. Martínez-Chantar M.L., Corrales F.J., Martínez-Cruz L.A., García-Trevijano E.R., Huang Z.Z., Chen L., Kanel G., Avila M.A., Mato J.M., Lu S.C. Spontaneous oxidative stress and liver tumors in mice lacking methionine adenosyltransferase 1A. FASEB J. 2002, 16:1292-1294.
81. Pietrangelo A. Iron in NASH, chronic liver diseases and HCC: how much iron is too much?. J. Hepatol. 2009, 50:249-251.
82. Pietrangelo A. Iron chelation beyond transfusion iron overload. Am. J. Hematol. 2007, 82:1142-1146.
83. Sorrentino P., D'Angelo S., Ferbo U., Micheli P., Bracigliano A., Vecchione R. Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis. J. Hepatol. 2009, 50:351-357.
84. Abergel A., Ruivard M., Bonny C. Iron overload and chronic liver diseases. Rev. Prat. 2006, 56:2130-2134.
85. Kew M.C. Hepatic iron overload and hepatocellular carcinoma. Cancer Lett. 2009, 286:38-43.
86. Ba Q., Hao M., Huang H., Hou J., Ge S., Zhang Z., Yin J., Chu R., Jiang H., Wang F., Chen K., Liu H., Wang H. Iron deprivation suppresses hepatocellular carcinoma growth in experimental studies. Clin. Cancer Res. 2011, 17:7625-7633.